Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Flotetuzumab - MacroGenics/Servier

Next Previous
X
Search
Drug Profile

Flotetuzumab - MacroGenics/Servier

Alternative Names: Anti-CD123/CD3-monoclonal-antibody-MGD006; CD123 x CD3; CD123xCD3-DART-bispecific-antibody-MGD006; CD123xCD3-dual-affinity-re-targeting-bispecific-antibody-MGD006; CD3xCD123-DART-molecule; MGD 006; RES-234; S 80880

Latest Information Update: 06 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MacroGenics
  • Developer MacroGenics; National Cancer Institute (USA); Servier
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes; Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 26 Jul 2024 Washington University School of Medicine terminates phase II trial in Acute myeloid leukemia in the US (IV) (NCT04582864)
  • 10 Dec 2022 Pharmacodynamics data from preclinical trial in Acute myeloid leukaemia presented at the 64nd Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2022)
  • 15 Sep 2022 MacroGenics terminated a phase-I/II trial due to business decision in Acute myeloid leukaemia (Recurrent, Second-line therapy or greater, Treatment-resistant) in US, UK, France, Italy, Germany, Netherlands, Israel and Spain (IV) (NCT02152956) (EudraCT2015-003813-11)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top